Sugammadex sodium

Summadex sodium injection, trade name bridion, is the world's first and only specific binding neuromuscular block antagonist developed by Merck. It's a modified γ- Cyclodextrin, by forming a complex with neuromuscular blocking drugs rocuronium or vecuronium in plasma, can reduce the number of neuromuscular blocking drugs combined with nicotinic receptors at neuromuscular junction, thus antagonizing neuromuscular block induced by rocuronium or vecuronium.